Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Impact of Pelvic Lymph Node Dissection on Oncological Outcomes in Patients with Clinically Staged Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Systematic Review - Beyond the ...

Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

First Use of the FloStent™ for Catheter-Dependent Urinary Retention Secondary to BPH: Additional Results from the RAPID I Study - Beyond the Abstract ...

Read the Full Video Transcript Diane Newman: Welcome to UroToday's Bladder Health Center of Excellence. I am Diane Newman, the center's Editor, and Adjunct Professor of Urology and Surgery at the ...

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...

Role of Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Seminoma: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer - Beyond the Abstract ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17 th and 21 st was host to the session Mini oral session: GU tumours, ...

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.